Drug intelligence / Profile preview

MAb-11-22.1

Development stage: Preclinical
Lead developer: MedAbome
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MAb-11-22.1 is a monoclonal antibody currently in preclinical development by MedAbome. It is being investigated for the treatment of both solid tumors and hematologic malignancies. The antibody targets a specific, though currently undisclosed, antigen designated as TBD-1. As part of MedAbome's oncology pipeline, this therapeutic candidate represents an early-stage effort to address various neoplastic conditions through targeted immunotherapy. The drug is currently undergoing preclinical and IND-enabling studies to support future clinical trials.

Targets

TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on MAb-11-22.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAb-11-22.1.

Explore the full profile